Anthracycline heart failure risk quantified for breast cancer, lymphoma patients
Patients who receive an anthracycline during treatment for breast cancer or lymphoma are more than three times as likely to develop congestive heart failure than healthy individuals, indicates a case–control study published in JAMA Network Open.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
